Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Mahboob Rahman(FIND), Carol Stanford(University of Missouri–Kansas City), Clive Rosendorff(Icahn School of Medicine at Mount Sinai), Sithiporn Sastrasinh(VA New Jersey Health Care System), Anne M. Huml(MetroHealth), Barry R. Davis(National Institutes of Health), Jan Basile(Medical University of South Carolina), Mario Henriquez, Charles Baimbridge, Gail T. Louis(United States Department of Veterans Affairs), Nelson Kopyt, Sara Pressel(Rutgers, The State University of New Jersey), Joshua I. Barzilay(Kaiser Permanente)
American Journal of Kidney Diseases
August 4, 2008
10.1053/j.ajkd.2008.05.027
Cited by 84

Related Papers

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia
|JAMA|2019|1.2k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
|Endocrine Practice|2016|875
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785